{"generic":"Ethinyl Estradiol\/Norelgestromin","drugs":["Ethinyl Estradiol\/Norelgestromin","Ortho Evra","Xulane"],"mono":{"0":{"id":"926960-s-0","title":"Generic Names","mono":"Ethinyl Estradiol\/Norelgestromin"},"1":{"id":"926960-s-1","title":"Dosing and Indications","sub":{"0":{"id":"926960-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Contraception:<\/b> apply 1 patch (ethinyl estradiol 35 mcg\/day and norelgestromin 150 mcg\/day) TOPICALLY each week for 3 weeks to clean, dry, intact skin on the buttock, abdomen, upper outer arm, or upper torso; week 4 is patch-free, withdrawal bleeding expected at this time; repeat cycle<\/li><li><b>Contraception:<\/b> initiate therapy on the day menstruation begins (first day start) or on the first Sunday after menstruation begins (Sunday start)<\/li><li><b>Contraception:<\/b> postpartum use in women who choose not to breastfeed should begin no sooner than 4 weeks after childbirth<\/li><li><b>Contraception:<\/b> miscarriage or abortion; if in first trimester, initiate therapy immediately; if in second trimester, begin no sooner than 4 weeks after miscarriage or abortion<\/li><\/ul>"},"1":{"id":"926960-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>use of this product before menarche not indicated<\/li><li><b>Contraception:<\/b> after menarche, apply 1 patch (ethinyl estradiol 35 mcg\/day and norelgestromin 150 mcg\/day) TOPICALLY each week for 3 weeks to clean, dry, intact skin on the buttock, abdomen, upper outer arm, or upper torso; week 4 is patch-free, withdrawal bleeding expected at this time; repeat cycle<\/li><li><b>Contraception:<\/b> initiate therapy on the day menstruation begins (first day start) or on the first Sunday after menstruation begins (Sunday start)<\/li><\/ul>"},"3":{"id":"926960-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Contraception<br\/>"}}},"2":{"id":"926960-s-2","title":"Black Box Warning","mono":"<b>Transdermal (Patch, Extended Release)<\/b><br\/>Cigarette smoking increases the risk of serious cardiovascular side effects from hormonal contraceptive use. This risk increases with age and with the number of cigarettes smoked and is marked in women over 35 years of age. Women who are over 35 years of age and smoke should not use ethinyl estradiol\/norelgestromin. A significantly increased risk of venous thromboembolism was found among women aged 15 to 44 years who used ethinyl estradiol\/norelgestromin patch compared with oral contraceptives containing 30 to 35 mcg of ethinyl estradiol (EE) and either levonorgestrel or norgestimate. Increased estrogen exposure from the patch may increase the risk of adverse events, including venous thromboembolism, compared with oral contraceptives.<br\/>"},"3":{"id":"926960-s-3","title":"Contraindications\/Warnings","sub":[{"id":"926960-s-3-9","title":"Contraindications","mono":"<ul><li>breast cancer or other estrogen or progestin-sensitive cancer, current or history<\/li><li>cerebrovascular or coronary artery disease<\/li><li>cigarette smoking in women older than 35 years<\/li><li>deep vein thrombosis, current or history<\/li><li>diabetes mellitus with vascular disease<\/li><li>headaches with focal neurological symptoms or migraine headaches with aura<\/li><li>hypercoagulopathies, inherited or acquired<\/li><li>hypertension, uncontrolled<\/li><li>liver disease<\/li><li>liver tumors, benign or malignant<\/li><li>migraine headache in women older than 35 years<\/li><li>pregnancy<\/li><li>pulmonary embolism, current or past history<\/li><li>thrombogenic valvular or thrombogenic rhythm diseases of the heart (eg, subacute bacterial endocarditis with valvular disease or atrial fibrillation)<\/li><li>uterine bleeding (undiagnosed and abnormal)<\/li><\/ul>"},{"id":"926960-s-3-10","title":"Precautions","mono":"<ul><li>thromboembolic disorders, including thromboembolism, myocardial infarction, and cerebrovascular events (thrombotic and hemorrhagic stroke), may occur; increased risk with advancing age (older than 35 years), cigarette smoking (especially with high number of cigarettes smoked), and with underlying cardiovascular disease risk factors<\/li><li>transdermal patch associated with greater estrogen exposure compared with oral contraceptives; possible increased risk of serious adverse effects<\/li><li>venous thromboembolism has been reported, greater risk possible with use of patch compared with oral contraceptives<\/li><li>amenorrhea or oligomenorrhea may occur after discontinuation of therapy, especially if preexisting<\/li><li>angioedema, hereditary; symptoms may be exacerbated or induced<\/li><li>body weight 90 kg (198 pounds) or greater; contraception may be less effective<\/li><li>carcinoma of the breast or cervix may occur<\/li><li>chloasma may occur, especially with history of chloasma gravidarum; avoid exposure to sunlight or ultraviolet light<\/li><li>cholestasis, pregnancy-related or with hormonal contraceptive use, past history of; increased risk for recurrence<\/li><li>depression; exacerbation may occur; monitoring recommended; discontinuation recommended for significant depression<\/li><li>diabetes (including prediabetic women); decrease in glucose tolerance may occur; monitoring recommended<\/li><li>dyslipidemia, uncontrolled; exacerbation may occur; consider alternative contraception<\/li><li>gallbladder disease; exacerbation, recurrence, or acceleration of the development of the condition may occur<\/li><li>headache, exacerbation of or new onset, and recurrent, persistent, or severe, may occur; discontinuation of therapy may be required<\/li><li>hepatocellular carcinomas have occurred with long-term therapy (greater than 8 years)<\/li><li>hypertension, controlled; increased blood pressure may occur, especially in older women and with prolonged use; monitoring recommended<\/li><li>hypertriglyceridemia or personal or family history of; increased risk of pancreatitis<\/li><li>jaundice may occur; discontinue use<\/li><li>liver disease (ie, acute viral hepatitis or severe decompensated cirrhosis of liver); use not recommended<\/li><li>liver function, impaired; medication may be poorly metabolized; discontinuation may be warranted<\/li><li>migraine headache that increases in frequency or severity; evaluate and discontinue if necessary<\/li><li>pediatric patients before menarche; use not recommended<\/li><li>postpartum period; increased risk of thromboembolism, do not initiate therapy earlier than 4 weeks following delivery<\/li><li>retinal thrombosis has occurred; discontinue use if unexplained ocular symptoms emerge (eg, loss of vision, diplopia, proptosis, papilledema, retinal vascular lesions)<\/li><li>surgery; increased risk of postoperative thromboembolic complications; discontinue use at least 4 weeks prior to and for 2 weeks after elective surgery known to have increased thromboembolism risk and during prolonged immobilization<\/li><li>vaginal bleeding abnormalities, including breakthrough bleeding and spotting, may occur; rule out malignancy, other pathology, or pregnancy<\/li><li>report suspected adverse reactions to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"926960-s-3-11","title":"Pregnancy Category","mono":"<ul><li>Ethinyl Estradiol: X (FDA)<\/li><li>Ethinyl Estradiol: B3 (AUS)<\/li><li>Norelgestromin: X (FDA)<\/li><\/ul>"},{"id":"926960-s-3-12","title":"Breast Feeding","mono":"<ul><li>Ethinyl Estradiol: AAP: Maternal medication usually compatible with breastfeeding.<\/li><li>Ethinyl Estradiol: WHO: Avoid breastfeeding.<\/li><li>Ethinyl Estradiol: Micromedex: Milk effects are possible.<\/li><li>Norelgestromin: Micromedex: Infant risk has been demonstrated.<\/li><\/ul>"}]},"4":{"id":"926960-s-4","title":"Drug Interactions","sub":[{"id":"926960-s-4-13","title":"Contraindicated","mono":"<ul><li>Dasabuvir (theoretical)<\/li><li>Ombitasvir (established)<\/li><li>Paritaprevir (established)<\/li><li>Ritonavir (theoretical)<\/li><li>Tranexamic Acid (probable)<\/li><\/ul>"},{"id":"926960-s-4-14","title":"Major","mono":"<ul><li>Anagrelide (theoretical)<\/li><li>Aripiprazole (theoretical)<\/li><li>Boceprevir (probable)<\/li><li>Bupropion (theoretical)<\/li><li>Carbamazepine (probable)<\/li><li>Ceritinib (theoretical)<\/li><li>Clozapine (established)<\/li><li>Crizotinib (theoretical)<\/li><li>Dabrafenib (theoretical)<\/li><li>Darunavir (theoretical)<\/li><li>Donepezil (theoretical)<\/li><li>Eliglustat (theoretical)<\/li><li>Felbamate (probable)<\/li><li>Fentanyl (theoretical)<\/li><li>Idelalisib (theoretical)<\/li><li>Isotretinoin (theoretical)<\/li><li>Mitotane (theoretical)<\/li><li>Nilotinib (theoretical)<\/li><li>Paclitaxel (theoretical)<\/li><li>Paclitaxel Protein-Bound (theoretical)<\/li><li>Piperaquine (theoretical)<\/li><li>Pirfenidone (theoretical)<\/li><li>Siltuximab (theoretical)<\/li><li>Theophylline (theoretical)<\/li><li>Tizanidine (probable)<\/li><\/ul>"},{"id":"926960-s-4-15","title":"Moderate","mono":"<ul><li>Alprazolam (probable)<\/li><li>Amprenavir (probable)<\/li><li>Aprepitant (probable)<\/li><li>Atazanavir (probable)<\/li><li>Bacampicillin (probable)<\/li><li>Betamethasone (probable)<\/li><li>Bexarotene (probable)<\/li><li>Bosentan (probable)<\/li><li>Clarithromycin (probable)<\/li><li>Colesevelam (probable)<\/li><li>Cyclosporine (probable)<\/li><li>Delavirdine (probable)<\/li><li>Efavirenz (probable)<\/li><li>Eslicarbazepine Acetate (probable)<\/li><li>Etoricoxib (probable)<\/li><li>Etravirine (probable)<\/li><li>Fosamprenavir (established)<\/li><li>Fosaprepitant (probable)<\/li><li>Fosphenytoin (probable)<\/li><li>Ginseng (probable)<\/li><li>Griseofulvin (established)<\/li><li>Lamotrigine (established)<\/li><li>Licorice (probable)<\/li><li>Modafinil (probable)<\/li><li>Mycophenolate Mofetil (probable)<\/li><li>Mycophenolic Acid (probable)<\/li><li>Nelfinavir (probable)<\/li><li>Oxcarbazepine (probable)<\/li><li>Phenobarbital (probable)<\/li><li>Phenytoin (probable)<\/li><li>Prednisolone (established)<\/li><li>Primidone (probable)<\/li><li>Rifabutin (probable)<\/li><li>Rifampin (established)<\/li><li>Rifapentine (probable)<\/li><li>Roflumilast (probable)<\/li><li>Rosuvastatin (probable)<\/li><li>Rufinamide (probable)<\/li><li>Selegiline (probable)<\/li><li>St John's Wort (established)<\/li><li>Telaprevir (established)<\/li><li>Tipranavir (established)<\/li><li>Topiramate (probable)<\/li><li>Troglitazone (probable)<\/li><li>Troleandomycin (established)<\/li><li>Valdecoxib (probable)<\/li><li>Voriconazole (established)<\/li><li>Warfarin (probable)<\/li><\/ul>"}]},"5":{"id":"926960-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Application site reaction<\/li><li><b>Gastrointestinal:<\/b>Abdominal pain, Nausea<\/li><li><b>Neurologic:<\/b>Headache<\/li><li><b>Psychiatric:<\/b>Mood swings<\/li><li><b>Reproductive:<\/b>Breast finding, Dysmenorrhea<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Arterial thromboembolism, Hypertension, Myocardial infarction, Thrombophlebitis, Venous thrombosis<\/li><li><b>Gastrointestinal:<\/b>Disorder of gallbladder<\/li><li><b>Hepatic:<\/b>Benign neoplasm of liver, Neoplasm of liver<\/li><li><b>Neurologic:<\/b>Cerebral hemorrhage, Cerebral thrombosis<\/li><li><b>Respiratory:<\/b>Pulmonary embolism<\/li><\/ul>"},"6":{"id":"926960-s-6","title":"Drug Name Info","sub":{"0":{"id":"926960-s-6-17","title":"US Trade Names","mono":"<ul><li>Ortho Evra<\/li><li>Xulane<\/li><\/ul>"},"2":{"id":"926960-s-6-19","title":"Class","mono":"<ul><li>Contraceptive Combination<\/li><li>Estrogen<\/li><li>Monophasic Contraceptive Combination<\/li><li>Progestin<\/li><\/ul>"},"3":{"id":"926960-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"926960-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"926960-s-7","title":"Mechanism Of Action","mono":"Systemic: Contraceptive, systemic-norelgestromin and ethinyl estradiol combination acts by suppression of gonadotropins. The primary mechanism of this action is inhibition of ovulation. Other alterations include changes in the cervical mucus (which increase the difficulty of sperm entry into the uterus) and the endometrium (which reduce the likelihood of implantation).    <br\/>"},"8":{"id":"926960-s-8","title":"Pharmacokinetics","sub":[{"id":"926960-s-8-23","title":"Absorption","mono":"Transdermal: Rapid <br\/>"},{"id":"926960-s-8-24","title":"Distribution","mono":"<ul><li>Protein binding, norelgestromin and norgestrel: greater than 97%<\/li><li>Protein binding, ethinyl estradiol: extensively bound to serum albumin<\/li><\/ul>"},{"id":"926960-s-8-25","title":"Metabolism","mono":"<ul><li>Transdermal, norelgestromin: Hepatic: first pass; Major metabolite: norgestrel<\/li><li>Transdermal, ethinyl estradiol: Hepatic: first-pass<\/li><\/ul>"},{"id":"926960-s-8-26","title":"Excretion","mono":"Transdermal: fecal and renal <br\/>"},{"id":"926960-s-8-27","title":"Elimination Half Life","mono":"<ul><li>Transdermal: Norelgestromin: 28 h<\/li><li>Transdermal: Ethinyl estradiol: 17 h<\/li><\/ul>"}]},"9":{"id":"926960-s-9","title":"Administration","mono":"<b>Transdermal<\/b><br\/><ul><li>do not cut, damage, or alter the patch prior to application<\/li><li>each new patch should be applied to a new spot on the skin to help avoid irritation<\/li><li>do not apply to skin that is red, irritated, or cut<\/li><li>do not apply to the breasts<\/li><li>make-up, creams, lotions, powders, or other topical products should not be applied to the skin where the patch is or will be placed<\/li><li>every new patch should be applied on the same day each week and may occur at any time on that day<\/li><li>nonhormonal back-up contraception should be used if initial therapy starts after day 1 of menstruation or if the patch-free interval between cycles is longer than 7 days<\/li><li>if patch edge lifts, press down firmly with palm for 10 seconds and smooth out any wrinkles; if it does not stick completely, remove and apply a replacement patch<\/li><li>complete or partial patch detachment for less than 24 hours; reapply to the same place or replace with a new patch immediately<\/li><li>complete or partial patch detachment for 24 hours or more; stop current cycle and begin a new 4-week cycle; back-up contraception should be used for the first full week of the new cycle<\/li><li>missed patch change at the start of any patch cycle (week 1\/day 1); apply the first patch of the new cycle immediately, back-up contraception must be used for the first week of the new cycle<\/li><li>missed patch change in the middle of the patch cycle (week 2\/day 8 or week 3\/day 15); if within 48 hours, apply a new patch and the next patch should be applied on the usual patch change day; if 48 hours or longer, start a new 4-week cycle and back-up contraception must be used for one week<\/li><li>missed patch change at the end of the patch cycle (week 4\/day 22); remove immediately and start the next cycle on the usual patch change day<\/li><li>used patches still contain some hormones and must be safely disposed of in the trash<\/li><\/ul>"},"10":{"id":"926960-s-10","title":"Monitoring","mono":"<ul><li>annual medical and physical examination<\/li><li>blood glucose; in prediabetic and diabetic patients<\/li><li>lipids; in patient with hyperlipidemias<\/li><li>blood pressure; significant or persistent elevation in patients with hypertension, hypertension-related diseases, or renal disease of<\/li><li>breast exam; in women with nodules or a strong family history of breast cancer<\/li><li>signs fluid retention; in women with conditions which might be aggravated by fluid retention<\/li><li>symptoms of depression; in women with a history of depression<\/li><\/ul>"},"11":{"id":"926960-s-11","title":"How Supplied","mono":"<ul><li><b>Ortho Evra<\/b><br\/>Transdermal Patch, Extended Release: (Ethinyl Estradiol - Norelgestromin) 0.75 MG\/7 -6 MG\/7<br\/><\/li><li><b>Xulane<\/b><br\/>Transdermal Patch, Extended Release: (Ethinyl Estradiol - Norelgestromin) 35 MCG\/24 HR-150 MCG\/24 HR<br\/><\/li><\/ul>"},"13":{"id":"926960-s-13","title":"Clinical Teaching","mono":"<ul><li>Warn patient that drug does not prevent against HIV or other sexually transmitted diseases.<\/li><li>This drug may cause abdominal pain, nausea, headache, mood swings, or gallbladder disease.<\/li><li>Patient should report abnormal vaginal bleeding.<\/li><li>Instruct patient to report signs\/symptoms of serious cardiovascular events such as myocardial infarction, stroke, venous thrombosis, and pulmonary embolism.<\/li><li>Advise patient to report a sudden change in vision or migraine, as drug may cause retinal vascular thrombosis.<\/li><li>Patients who wear contact lenses should report visual changes or changes in lens tolerance.<\/li><li>Patients using the transdermal patch should not cut, damage, or alter the patch prior to application.<\/li><li>Advise patient to rotate skin sites when applying a new patch. Patch should never be applied to the breasts.<\/li><li>Avoid use of topical products (make-up, creams, lotions, powders, etc.) on the skin where patch is or will be placed.<\/li><li>Patients should not smoke during therapy, as this increases the risk of serious cardiovascular side effects.<\/li><li>Instruct patients to use an additional contraceptive method if the patch-free interval between menstrual cycles is longer than 7 days.<\/li><li>Patient should use a new patch if the old one falls off and cannot be reapplied. If the old patch is off for more than 24 h, patient should start a new patch cycle and use a back-up form of contraception for 7 days.<\/li><\/ul>"}}}